Clinical Trial Update: Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

An ongoing Phase 2 trial evaluating the anti-tumor effects of 2X-121 in patients with recurrent, advanced ovarian cancer. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• 2X-121

Snippet

Sponsor: Allarity Therapeutics | Conditions: Advanced Ovarian Cancer | Phase 2 | Status: RECRUITING